Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetravalent dengue vaccine (purified inactivated)
- Development stage
- Discontinued
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The tetravalent dengue purified inactivated vaccine (DPIV, also known as TDENV-PIV) is an investigational, formalin-inactivated whole-virus vaccine containing purified dengue virus types 1–4 (DENV-1 to DENV-4) propagated in Vero cells. Developed through a collaboration between the Walter Reed Army Institute of Research (WRAIR), GlaxoSmithKline (GSK), and Fiocruz, the vaccine was designed to prevent dengue fever by inducing neutralizing antibody responses against all four dengue virus serotypes. In clinical trials, formulations were evaluated with various adjuvants, including aluminum hydroxide (alum), AS01E, and AS03B, administered intramuscularly on a two-dose schedule. Although the vaccine demonstrated acceptable safety and induced robust peak neutralizing antibody titers, these responses waned relatively quickly, particularly in dengue-naive individuals. R&D has been discontinued, and no active clinical development is currently ongoing.
- Other names
- tetravalent dengue purified inactivated vaccinetetravalent dengue virus purified inactivated vaccine
Beyond the preview
Go deeper on tetravalent dengue vaccine (purified inactivated).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetravalent dengue vaccine (purified inactivated).